Beamline Diagnostics Limited

Life Sciences
Cancer Diagnosis
Aim of funding: 
HMRC Advance Assurance received: 

Beamline Diagnostics Limited


BeamLine Diagnostics was set up to commercialise research in to the application of infrared spectroscopy to the diagnosis of cancer. Cancer is a worldwide problem with over 14 million new diagnoses and 8 million deaths recorded in 2012 alone (according to Cancer Research UK statistics, May 2015).

The Company is developing a system that enables rapid, accurate and low-cost point-of-care screening of biopsies for pre-cancer/cancer.

This will save considerable time and money on more complex analyses and drastically reduce time to diagnosis for both healthy and pre-cancer/cancer patients. The patent-pending analytical software application works with a commercially available infrared spectrometer to quantify biochemical changes in pre-cancerous and cancerous tissue.


In NHS England, annually, approximately 670,000 patients undergo a biopsy procedure of the Gastrointestinal (GI) tract. On average 11 biopsies are collected per patient but this number can range from 1 or 2 to 40+. The average cost of each biopsy is £48 (ranging from £22 to £74) depending on the type of biopsy taken.

Currently the gold-standard method for diagnosing cancer is by taking a biopsy followed by microscopic analysis. This is a labour-intensive process that requires highly skill technicians. In NHS England alone, 1.14 million biopsy procedures were performed in 2012.

*Above numbers are based on statistics from 2011-2012 annual report of all procedures and interventions – HSCIC. Numbers include biopsy procedures only, excluding excisions.

Information on this webpage relates to and is provided by Deepbridge Advisers Limited.

The content of this webpage should not be construed as financial advice. Any decision to invest should be made only on the basis of the relevant documentation for each investment. Past performance is not necessarily a guide to future performance. The value of an investment may go down as well as up and investors may not get back the full amount invested. Investments in small unquoted companies carry an above-average level of risk. These investments are highly illiquid and as such, there may not be a readily available market to sell such an investment. Deepbridge Capital LLP, Deepbridge Advisers Limited and Enterprise Partners LLP (together "the Sponsors," or "Sponsor) do not provide specific individual advice on the suitability of investments with regard to a potential investor's individual circumstances, risk tolerance or investment objectives and investors should seek independent financial advice if they are in any doubt whether a product is suitable for them.